Consistent alteration of chain length-specific ceramides in human and mouse fibrotic kidneys
Several studies revealed alterations of single sphingolipid species, such as chain length-specific ceramides, in plasma and serum of patients with kidney diseases. Here, we investigated whether such alterations occur in kidney tissue from patients and mice suffering from renal fibrosis, the common e...
Gespeichert in:
| Veröffentlicht in: | Biochimica et biophysica acta. Molecular and cell biology of lipids Jg. 1866; H. 1; S. 158821 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Netherlands
Elsevier B.V
01.01.2021
|
| Schlagworte: | |
| ISSN: | 1388-1981, 1879-2618, 1879-2618 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Several studies revealed alterations of single sphingolipid species, such as chain length-specific ceramides, in plasma and serum of patients with kidney diseases. Here, we investigated whether such alterations occur in kidney tissue from patients and mice suffering from renal fibrosis, the common endpoint of chronic kidney diseases.
Human fibrotic kidney samples were collected from nephrectomy specimens with hydronephrosis and/or pyelonephritis. Healthy parts from tumor nephrectomies served as nonfibrotic controls. Mouse fibrotic kidney samples were collected from male C57BL/6J mice treated with an adenine-rich diet for 14 days or were subjected to 7 days of unilateral ureteral obstruction (UUO). Kidneys of untreated mice and contralateral kidneys (UUO) served as respective controls. Sphingolipid levels were detected by LC-MS/MS. Fibrotic markers were analyzed by TaqMan® analysis and immunohistology.
Very long-chain ceramides Cer d18:1/24:0 and Cer d18:1/24:1 were significantly downregulated in both fibrotic human kidney cortex and fibrotic murine kidney compared to respective control samples. These effects correlate with upregulation of COL1α1, COL3α1 and αSMA expression in fibrotic human kidney cortex and fibrotic mouse kidney.
We have shown that very long-chain ceramides Cer d18:1/24:0 and Cer d18:1/24:1 are consistently downregulated in fibrotic kidney samples from human and mouse. Our findings support the use of in vivo murine models as appropriate translational means to understand the involvement of ceramides in human kidney diseases. In addition, our study raises interesting questions about the possible manipulation of ceramide metabolism to prevent progression of fibrosis and the use of ceramides as potential biomarkers of chronic kidney disease.
•Very long-chain ceramides are downregulated in fibrotic renal tissue.•Regulation of ceramides in fibrotic kidneys is similar in mice and men.•Different ceramide profile in human renal cortex compared to renal medulla |
|---|---|
| AbstractList | Several studies revealed alterations of single sphingolipid species, such as chain length-specific ceramides, in plasma and serum of patients with kidney diseases. Here, we investigated whether such alterations occur in kidney tissue from patients and mice suffering from renal fibrosis, the common endpoint of chronic kidney diseases.BACKGROUNDSeveral studies revealed alterations of single sphingolipid species, such as chain length-specific ceramides, in plasma and serum of patients with kidney diseases. Here, we investigated whether such alterations occur in kidney tissue from patients and mice suffering from renal fibrosis, the common endpoint of chronic kidney diseases.Human fibrotic kidney samples were collected from nephrectomy specimens with hydronephrosis and/or pyelonephritis. Healthy parts from tumor nephrectomies served as nonfibrotic controls. Mouse fibrotic kidney samples were collected from male C57BL/6J mice treated with an adenine-rich diet for 14 days or were subjected to 7 days of unilateral ureteral obstruction (UUO). Kidneys of untreated mice and contralateral kidneys (UUO) served as respective controls. Sphingolipid levels were detected by LC-MS/MS. Fibrotic markers were analyzed by TaqMan® analysis and immunohistology.METHODSHuman fibrotic kidney samples were collected from nephrectomy specimens with hydronephrosis and/or pyelonephritis. Healthy parts from tumor nephrectomies served as nonfibrotic controls. Mouse fibrotic kidney samples were collected from male C57BL/6J mice treated with an adenine-rich diet for 14 days or were subjected to 7 days of unilateral ureteral obstruction (UUO). Kidneys of untreated mice and contralateral kidneys (UUO) served as respective controls. Sphingolipid levels were detected by LC-MS/MS. Fibrotic markers were analyzed by TaqMan® analysis and immunohistology.Very long-chain ceramides Cer d18:1/24:0 and Cer d18:1/24:1 were significantly downregulated in both fibrotic human kidney cortex and fibrotic murine kidney compared to respective control samples. These effects correlate with upregulation of COL1α1, COL3α1 and αSMA expression in fibrotic human kidney cortex and fibrotic mouse kidney.RESULTSVery long-chain ceramides Cer d18:1/24:0 and Cer d18:1/24:1 were significantly downregulated in both fibrotic human kidney cortex and fibrotic murine kidney compared to respective control samples. These effects correlate with upregulation of COL1α1, COL3α1 and αSMA expression in fibrotic human kidney cortex and fibrotic mouse kidney.We have shown that very long-chain ceramides Cer d18:1/24:0 and Cer d18:1/24:1 are consistently downregulated in fibrotic kidney samples from human and mouse. Our findings support the use of in vivo murine models as appropriate translational means to understand the involvement of ceramides in human kidney diseases. In addition, our study raises interesting questions about the possible manipulation of ceramide metabolism to prevent progression of fibrosis and the use of ceramides as potential biomarkers of chronic kidney disease.CONCLUSIONWe have shown that very long-chain ceramides Cer d18:1/24:0 and Cer d18:1/24:1 are consistently downregulated in fibrotic kidney samples from human and mouse. Our findings support the use of in vivo murine models as appropriate translational means to understand the involvement of ceramides in human kidney diseases. In addition, our study raises interesting questions about the possible manipulation of ceramide metabolism to prevent progression of fibrosis and the use of ceramides as potential biomarkers of chronic kidney disease. Several studies revealed alterations of single sphingolipid species, such as chain length-specific ceramides, in plasma and serum of patients with kidney diseases. Here, we investigated whether such alterations occur in kidney tissue from patients and mice suffering from renal fibrosis, the common endpoint of chronic kidney diseases. Human fibrotic kidney samples were collected from nephrectomy specimens with hydronephrosis and/or pyelonephritis. Healthy parts from tumor nephrectomies served as nonfibrotic controls. Mouse fibrotic kidney samples were collected from male C57BL/6J mice treated with an adenine-rich diet for 14 days or were subjected to 7 days of unilateral ureteral obstruction (UUO). Kidneys of untreated mice and contralateral kidneys (UUO) served as respective controls. Sphingolipid levels were detected by LC-MS/MS. Fibrotic markers were analyzed by TaqMan® analysis and immunohistology. Very long-chain ceramides Cer d18:1/24:0 and Cer d18:1/24:1 were significantly downregulated in both fibrotic human kidney cortex and fibrotic murine kidney compared to respective control samples. These effects correlate with upregulation of COL1α1, COL3α1 and αSMA expression in fibrotic human kidney cortex and fibrotic mouse kidney. We have shown that very long-chain ceramides Cer d18:1/24:0 and Cer d18:1/24:1 are consistently downregulated in fibrotic kidney samples from human and mouse. Our findings support the use of in vivo murine models as appropriate translational means to understand the involvement of ceramides in human kidney diseases. In addition, our study raises interesting questions about the possible manipulation of ceramide metabolism to prevent progression of fibrosis and the use of ceramides as potential biomarkers of chronic kidney disease. Several studies revealed alterations of single sphingolipid species, such as chain length-specific ceramides, in plasma and serum of patients with kidney diseases. Here, we investigated whether such alterations occur in kidney tissue from patients and mice suffering from renal fibrosis, the common endpoint of chronic kidney diseases. Human fibrotic kidney samples were collected from nephrectomy specimens with hydronephrosis and/or pyelonephritis. Healthy parts from tumor nephrectomies served as nonfibrotic controls. Mouse fibrotic kidney samples were collected from male C57BL/6J mice treated with an adenine-rich diet for 14 days or were subjected to 7 days of unilateral ureteral obstruction (UUO). Kidneys of untreated mice and contralateral kidneys (UUO) served as respective controls. Sphingolipid levels were detected by LC-MS/MS. Fibrotic markers were analyzed by TaqMan® analysis and immunohistology. Very long-chain ceramides Cer d18:1/24:0 and Cer d18:1/24:1 were significantly downregulated in both fibrotic human kidney cortex and fibrotic murine kidney compared to respective control samples. These effects correlate with upregulation of COL1α1, COL3α1 and αSMA expression in fibrotic human kidney cortex and fibrotic mouse kidney. We have shown that very long-chain ceramides Cer d18:1/24:0 and Cer d18:1/24:1 are consistently downregulated in fibrotic kidney samples from human and mouse. Our findings support the use of in vivo murine models as appropriate translational means to understand the involvement of ceramides in human kidney diseases. In addition, our study raises interesting questions about the possible manipulation of ceramide metabolism to prevent progression of fibrosis and the use of ceramides as potential biomarkers of chronic kidney disease. •Very long-chain ceramides are downregulated in fibrotic renal tissue.•Regulation of ceramides in fibrotic kidneys is similar in mice and men.•Different ceramide profile in human renal cortex compared to renal medulla Several studies revealed alterations of single sphingolipid species, such as chain length-specific ceramides, in plasma and serum of patients with kidney diseases. Here, we investigated whether such alterations occur in kidney tissue from patients and mice suffering from renal fibrosis, the common endpoint of chronic kidney diseases.Human fibrotic kidney samples were collected from nephrectomy specimens with hydronephrosis and/or pyelonephritis. Healthy parts from tumor nephrectomies served as nonfibrotic controls. Mouse fibrotic kidney samples were collected from male C57BL/6J mice treated with an adenine-rich diet for 14 days or were subjected to 7 days of unilateral ureteral obstruction (UUO). Kidneys of untreated mice and contralateral kidneys (UUO) served as respective controls. Sphingolipid levels were detected by LC-MS/MS. Fibrotic markers were analyzed by TaqMan® analysis and immunohistology.Very long-chain ceramides Cer d18:1/24:0 and Cer d18:1/24:1 were significantly downregulated in both fibrotic human kidney cortex and fibrotic murine kidney compared to respective control samples. These effects correlate with upregulation of COL1α1, COL3α1 and αSMA expression in fibrotic human kidney cortex and fibrotic mouse kidney.We have shown that very long-chain ceramides Cer d18:1/24:0 and Cer d18:1/24:1 are consistently downregulated in fibrotic kidney samples from human and mouse. Our findings support the use of in vivo murine models as appropriate translational means to understand the involvement of ceramides in human kidney diseases. In addition, our study raises interesting questions about the possible manipulation of ceramide metabolism to prevent progression of fibrosis and the use of ceramides as potential biomarkers of chronic kidney disease. |
| ArticleNumber | 158821 |
| Author | Djudjaj, Sonja Patyna, Sammy Eckes, Timon Thomas, Dominique Koch, Alexander Gauer, Stefan Trautmann, Sandra Pfeilschifter, Josef Beyer, Sandra Boor, Peter Schaefer, Liliana Schwalm, Stephanie |
| Author_xml | – sequence: 1 givenname: Timon surname: Eckes fullname: Eckes, Timon email: eckes@em.uni-frankfurt.de organization: Institute of General Pharmacology and Toxicology, University Hospital, Goethe University Frankfurt am Main, Germany – sequence: 2 givenname: Sandra surname: Trautmann fullname: Trautmann, Sandra organization: Institute of Clinical Pharmacology, University Hospital, Goethe University Frankfurt am Main, Germany – sequence: 3 givenname: Sonja surname: Djudjaj fullname: Djudjaj, Sonja organization: Institute of Pathology, University Hospital of the RWTH Aachen, Germany – sequence: 4 givenname: Sandra surname: Beyer fullname: Beyer, Sandra organization: Institute of General Pharmacology and Toxicology, University Hospital, Goethe University Frankfurt am Main, Germany – sequence: 5 givenname: Sammy surname: Patyna fullname: Patyna, Sammy organization: Department of Nephrology, University Hospital, Goethe University Frankfurt am Main, Germany – sequence: 6 givenname: Stephanie surname: Schwalm fullname: Schwalm, Stephanie organization: Institute of General Pharmacology and Toxicology, University Hospital, Goethe University Frankfurt am Main, Germany – sequence: 7 givenname: Stefan surname: Gauer fullname: Gauer, Stefan organization: Department of Nephrology, University Hospital, Goethe University Frankfurt am Main, Germany – sequence: 8 givenname: Dominique surname: Thomas fullname: Thomas, Dominique organization: Institute of Clinical Pharmacology, University Hospital, Goethe University Frankfurt am Main, Germany – sequence: 9 givenname: Liliana surname: Schaefer fullname: Schaefer, Liliana organization: Institute of General Pharmacology and Toxicology, University Hospital, Goethe University Frankfurt am Main, Germany – sequence: 10 givenname: Peter surname: Boor fullname: Boor, Peter organization: Institute of Pathology, University Hospital of the RWTH Aachen, Germany – sequence: 11 givenname: Alexander surname: Koch fullname: Koch, Alexander organization: Institute of General Pharmacology and Toxicology, University Hospital, Goethe University Frankfurt am Main, Germany – sequence: 12 givenname: Josef surname: Pfeilschifter fullname: Pfeilschifter, Josef organization: Institute of General Pharmacology and Toxicology, University Hospital, Goethe University Frankfurt am Main, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33010454$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUtrHDEQhEWwiR_JPwhGx1xmreesxodAWOIHGHyxbwEhaXqy2sxIa0lr8L-P1mNffIhPLVpfFU3VCToIMQBC3yhZUELb883CWjP67YIRVldSKUY_oWOqll3DWqoO6psr1dBO0SN0kvOGECo5l5_REeeEEiHFMfq9iiH7XCAUbMYCyRQfA44DdmvjAx4h_CnrJm_B-cE77Cox-R4yrp_r3WQCNqHHU9xlwIO3KZZK_fV9gOf8BR0OZszw9XWeoofLX_er6-b27upm9fO2cbyTpel7KaxyYlAdWVrSAmWcsqFlpm05txLIwMmy64ySZEmZ5IYZLihYqyQ42fJT9H323ab4uINc9OSzg3E0AephmkkmOFUtkR-jQihBFFN79OwV3dkJer1NfjLpWb-FV4GLGXAp5pxg0M6Xl_xKMn7UlOh9U3qj56b0vik9N1XF4p34zf8D2Y9ZBjXPJw9JZ-chOOh9Ald0H_3_Df4B1imttw |
| CitedBy_id | crossref_primary_10_1152_ajprenal_00193_2024 crossref_primary_10_3390_cancers13020270 crossref_primary_10_3389_fcvm_2025_1656113 crossref_primary_10_3389_fmicb_2023_1085818 crossref_primary_10_3390_jcm13175050 crossref_primary_10_1016_j_fct_2022_113333 crossref_primary_10_1038_s41598_024_68270_5 crossref_primary_10_3389_fendo_2020_622692 |
| Cites_doi | 10.3390/ijms17060922 10.1053/j.ajkd.2009.11.016 10.1093/ndt/gfw427 10.1126/science.1260419 10.3390/ijms19051390 10.3748/wjg.15.6068 10.2337/db08-1228 10.1073/pnas.1005572107 10.1161/ATVBAHA.118.311199 10.1016/j.talanta.2019.120593 10.1161/ATVBAHA.116.307497 10.1016/j.clinbiochem.2015.08.001 10.1074/jbc.M115.695858 10.1177/0961203316686707 10.1053/j.ajkd.2019.01.001 10.1042/BJ20050291 10.1073/pnas.0305799101 10.1681/ASN.2014050508 10.1186/1476-511X-12-98 10.1002/iub.319 10.1016/j.plipres.2016.03.006 10.1074/jbc.M109.077594 10.1007/s10875-012-9710-3 10.1016/j.prostaglandins.2019.106348 10.1074/jbc.M707386200 10.1038/nrm.2017.107 10.1007/s00467-013-2642-1 10.1681/ASN.2017020190 10.1164/rccm.200905-0799OC 10.1038/sj.ki.5000357 10.1016/j.plipres.2011.11.001 10.1194/jlr.M076745 10.1074/jbc.M109.078121 |
| ContentType | Journal Article |
| Copyright | 2020 Elsevier B.V. Copyright © 2020 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2020 Elsevier B.V. – notice: Copyright © 2020 Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 |
| DOI | 10.1016/j.bbalip.2020.158821 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE AGRICOLA |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Chemistry Biology |
| EISSN | 1879-2618 |
| ExternalDocumentID | 33010454 10_1016_j_bbalip_2020_158821 S1388198120302134 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 23N 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXUO ABEFU ABFNM ABGSF ABMAC ABUDA ABXDB ABYKQ ACDAQ ACIUM ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEHWI AEKER AFKWA AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC CS3 DOVZS EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 PC. Q38 R2- ROL RPZ SDF SDG SDP SES SEW SSU SSZ T5K XJT XPP ~G- 9DU AAHBH AATTM AAXKI AAYWO AAYXX ABWVN ACLOT ACRPL ADNMO AEIPS AFJKZ AGQPQ AIIUN ANKPU CITATION EFKBS ~HD CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c395t-dd54b8c4f8907b06e12312f62a6633b5e0f30799a85071253a2a341ebb85ec563 |
| ISICitedReferencesCount | 11 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000592664200010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1388-1981 1879-2618 |
| IngestDate | Wed Oct 01 13:59:25 EDT 2025 Thu Oct 02 10:56:32 EDT 2025 Wed Feb 19 02:28:05 EST 2025 Sat Nov 29 07:02:17 EST 2025 Tue Nov 18 21:02:51 EST 2025 Fri Feb 23 02:48:22 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Sphingolipids AN Lipid mediator ECM UUO Kidney Cer LC-MS/MS S1P Nephropathy Fibrosis Ceramide CerS CKD |
| Language | English |
| License | Copyright © 2020 Elsevier B.V. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c395t-dd54b8c4f8907b06e12312f62a6633b5e0f30799a85071253a2a341ebb85ec563 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 33010454 |
| PQID | 2448408285 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2524318605 proquest_miscellaneous_2448408285 pubmed_primary_33010454 crossref_citationtrail_10_1016_j_bbalip_2020_158821 crossref_primary_10_1016_j_bbalip_2020_158821 elsevier_sciencedirect_doi_10_1016_j_bbalip_2020_158821 |
| PublicationCentury | 2000 |
| PublicationDate | January 2021 2021-01-00 20210101 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: January 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Biochimica et biophysica acta. Molecular and cell biology of lipids |
| PublicationTitleAlternate | Biochim Biophys Acta Mol Cell Biol Lipids |
| PublicationYear | 2021 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Saran, Robinson, Abbott, Agodoa, Bragg-Gresham, Balkrishnan, Bhave, Dietrich, Ding, Eggers, Gaipov, Gillen, Gipson, Gu, Guro, Haggerty, Han, He, Herman, Heung, Hirth, Hsiung, Hutton, Inoue, Jacobsen, Jin, Kalantar-Zadeh, Kapke, Kleine, Kovesdy, Krueter, Kurtz, Li, Liu, Marroquin, McCullough, Molnar, Modi, Montez-Rath, Moradi, Morgenstern, Mukhopadhyay, Nallamothu, Nguyen, Norris, O’Hare, Obi, Park, Pearson, Pisoni, Potukuchi, Repeck, Rhee, Schaubel, Schrager, Selewski, Shamraj, Shaw, Shi, Shieu, Sim, Soohoo, Steffick, Streja, Sumida, Tamura, Tilea, Turf, Wang, Weng, Woodside, Wyncott, Xiang, Xin, Yin, You, Zhang, Zhou, Shahinian, Renal Data System (bb0005) 2019; 73 H. Geidis, Praktische Mikroskopie, in: Praktische Mikroskopie, 1935: p. 28f. Grösch, Schiffmann, Geisslinger (bb0025) 2012; 51 Sun, Wang, Zhang, Yu, Chen, Zhao (bb0060) 2017; 32 Kajander, Myllyluoma, Kyrönpalo, Rasmussen, Sipponen, Mattila, Seppänen-Laakso, Vapaatalo, Oresic, Korpela (bb0105) 2009; 15 Bekpinar, Yenidunya, Gurdol, Unlucerci, Aycan-Ustyol, Dinccag (bb0070) 2015; 48 Hahnefeld, Gurke, Thomas, Schreiber, Schäfer, Trautmann, Snodgrass, Kratz, Geisslinger, Ferreirós (bb0130) 2020; 209 Siskind, Mullen, Romero Rosales, Clarke, Hernandez-Corbacho, Edinger, Obeid (bb0160) 2010; 285 Haus, Kashyap, Kasumov, Zhang, Kelly, Defronzo, Kirwan (bb0045) 2009; 58 Cutler, Kelly, Storie, Pedersen, Tammara, Hatanpaa, Troncoso, Mattson (bb0100) 2004; 101 Galadari, Rahman, Pallichankandy, Galadari, Thayyullathil (bb0080) 2013; 12 Sassa, Hirayama, Kihara (bb0165) 2016; 291 Yoo, Thornhill, Forbes, Coleman, Marcinko, Liaw, Chevalier (bb0190) 2006; 70 T.V. Dupre, M.A. Doll, P.P. Shah, C.N. Sharp, D. Siow, J. Megyesi, J. Shayman, A. Bielwska, J. Bielawski, L.J. Beverly, others, Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury, Journal of Lipid Research. (2017) jlr–M076745. Watson, Tullus, Marks, Holt, Pilkington, Beresford (bb0065) 2012; 32 Wegner, Schiffmann, Parnham, Geisslinger, Grösch (bb0180) 2016; 63 Ohno, Suto, Yamanaka, Mizutani, Mitsutake, Igarashi, Sassa, Kihara (bb0175) 2010; 107 Mizutani, Kihara, Igarashi (bb0170) 2005; 390 Havulinna, Sysi-Aho, Hilvo, Kauhanen, Hurme, Ekroos, Salomaa, Laaksonen (bb0055) 2016; 36 Pewzner-Jung, Park, Laviad, Silva, Lahiri, Stiban, Erez-Roman, Brügger, Sachsenheimer, Wieland, Prieto, Merrill, Futerman (bb0150) 2010; 285 K. Kuć, P. Kiciński, S. Przybylska-Kuć, J. Mosiewicz, W. Myśliński, [Serum creatinine level and eGFR as the indices of renal function in present-day clinical practice], Prz. Lek. 67 (2010) 491–495. Patyna, Büttner, Eckes, Obermüller, Bartel, Braner, Trautmann, Thomas, Geiger, Pfeilschifter, Koch (bb0090) 2019; 144 Eum, Lee, Yi, Kim, Seong, Moon (bb0135) 2020; 460849 Checa, Idborg, Zandian, Sar, Surowiec, Trygg, Svenungsson, Jakobsson, Nilsson, Gunnarsson, Wheelock (bb0075) 2017; 26 Hannun, Obeid (bb0020) 2018; 19 Nowling, Mather, Thiyagarajan, Hernández-Corbacho, Powers, Jones, Snider, Oates, Drake, Siskind (bb0110) 2015; 26 Sung, Woo, Lee (bb0185) 2000; 34 Schwalm, Beyer, Frey, Haceni, Grammatikos, Thomas, Geisslinger, Schaefer, Huwiler, Pfeilschifter (bb0115) 2017 Meeusen, Donato, Bryant, Baudhuin, Berger, Jaffe (bb0050) 2018; 38 . Laviad, Albee, Pankova-Kholmyansky, Epstein, Park, Merrill, Futerman (bb0145) 2008; 283 Djudjaj, Martin, Buhl, Nothofer, Leng, Piecychna, Floege, Bernhagen, Bucala, Boor (bb0120) 2017; 28 R. Brunkhorst, W. Pfeilschifter, S. Patyna, S. Büttner, T. Eckes, S. Trautmann, D. Thomas, J. Pfeilschifter, A. Koch, Preanalytical biases in the measurement of human blood sphingolipids, Int J Mol Sci. 19 (2018). doi Brodlie, McKean, Johnson, Gray, Fisher, Corris, Lordan, Ward (bb0095) 2010; 182 Levy, Futerman (bb0140) 2010; 62 Mitsnefes, Scherer, Friedman, Gordillo, Furth, Warady (bb0085) 2014; 29 T.J. Hoerger, J.S. Wittenborn, J.E. Segel, N.R. Burrows, K. Imai, P. Eggers, M.E. Pavkov, R. Jordan, S.M. Hailpern, A.C. Schoolwerth, D.E. Williams, A health policy model of CKD: 1. Model construction, assumptions, and validation of health consequences, American Journal of Kidney Diseases. 55 (2010) 452–462. doi G. Grammatikos, J. Dietz, N. Ferreiros, A. Koch, G. Dultz, D. Bon, I. Karakasiliotis, T. Lutz, G. Knecht, P. Gute, E. Herrmann, S. Zeuzem, P. Mavromara, C. Sarrazin, J. Pfeilschifter, Persistence of HCV in acutely-infected patients depletes C24-ceramide and upregulates sphingosine and sphinganine serum levels, Int J Mol Sci. 17 (2016). doi Matanes, Twal, Hammad (bb0035) 2019 M. Uhlén, L. Fagerberg, B.M. Hallström, C. Lindskog, P. Oksvold, A. Mardinoglu, Å. Sivertsson, C. Kampf, E. Sjöstedt, A. Asplund, I. Olsson, K. Edlund, E. Lundberg, S. Navani, C.A.-K. Szigyarto, J. Odeberg, D. Djureinovic, J.O. Takanen, S. Hober, T. Alm, P.-H. Edqvist, H. Berling, H. Tegel, J. Mulder, J. Rockberg, P. Nilsson, J.M. Schwenk, M. Hamsten, K. von Feilitzen, M. Forsberg, L. Persson, F. Johansson, M. Zwahlen, G. von Heijne, J. Nielsen, F. Pontén, Tissue-based map of the human proteome, Science. 347 (2015). doi Ohno (10.1016/j.bbalip.2020.158821_bb0175) 2010; 107 Sung (10.1016/j.bbalip.2020.158821_bb0185) 2000; 34 Patyna (10.1016/j.bbalip.2020.158821_bb0090) 2019; 144 Cutler (10.1016/j.bbalip.2020.158821_bb0100) 2004; 101 Galadari (10.1016/j.bbalip.2020.158821_bb0080) 2013; 12 Mitsnefes (10.1016/j.bbalip.2020.158821_bb0085) 2014; 29 Pewzner-Jung (10.1016/j.bbalip.2020.158821_bb0150) 2010; 285 Grösch (10.1016/j.bbalip.2020.158821_bb0025) 2012; 51 Checa (10.1016/j.bbalip.2020.158821_bb0075) 2017; 26 10.1016/j.bbalip.2020.158821_bb0010 Nowling (10.1016/j.bbalip.2020.158821_bb0110) 2015; 26 10.1016/j.bbalip.2020.158821_bb0155 Sun (10.1016/j.bbalip.2020.158821_bb0060) 2017; 32 10.1016/j.bbalip.2020.158821_bb0030 10.1016/j.bbalip.2020.158821_bb0195 Matanes (10.1016/j.bbalip.2020.158821_bb0035) 2019 Wegner (10.1016/j.bbalip.2020.158821_bb0180) 2016; 63 10.1016/j.bbalip.2020.158821_bb0015 Sassa (10.1016/j.bbalip.2020.158821_bb0165) 2016; 291 Levy (10.1016/j.bbalip.2020.158821_bb0140) 2010; 62 Meeusen (10.1016/j.bbalip.2020.158821_bb0050) 2018; 38 Eum (10.1016/j.bbalip.2020.158821_bb0135) 2020; 460849 Yoo (10.1016/j.bbalip.2020.158821_bb0190) 2006; 70 Kajander (10.1016/j.bbalip.2020.158821_bb0105) 2009; 15 Havulinna (10.1016/j.bbalip.2020.158821_bb0055) 2016; 36 Brodlie (10.1016/j.bbalip.2020.158821_bb0095) 2010; 182 Bekpinar (10.1016/j.bbalip.2020.158821_bb0070) 2015; 48 Hahnefeld (10.1016/j.bbalip.2020.158821_bb0130) 2020; 209 Saran (10.1016/j.bbalip.2020.158821_bb0005) 2019; 73 Schwalm (10.1016/j.bbalip.2020.158821_bb0115) 2017 Hannun (10.1016/j.bbalip.2020.158821_bb0020) 2018; 19 10.1016/j.bbalip.2020.158821_bb0040 Laviad (10.1016/j.bbalip.2020.158821_bb0145) 2008; 283 Watson (10.1016/j.bbalip.2020.158821_bb0065) 2012; 32 Haus (10.1016/j.bbalip.2020.158821_bb0045) 2009; 58 Mizutani (10.1016/j.bbalip.2020.158821_bb0170) 2005; 390 Djudjaj (10.1016/j.bbalip.2020.158821_bb0120) 2017; 28 Siskind (10.1016/j.bbalip.2020.158821_bb0160) 2010; 285 10.1016/j.bbalip.2020.158821_bb0125 |
| References_xml | – volume: 73 start-page: A7 year: 2019 end-page: A8 ident: bb0005 article-title: 2018 annual data report: epidemiology of kidney disease in the United States publication-title: Am. J. Kidney Dis. – reference: K. Kuć, P. Kiciński, S. Przybylska-Kuć, J. Mosiewicz, W. Myśliński, [Serum creatinine level and eGFR as the indices of renal function in present-day clinical practice], Prz. Lek. 67 (2010) 491–495. – volume: 32 start-page: 1019 year: 2012 end-page: 1025 ident: bb0065 article-title: Increased serum concentration of sphingosine-1-phosphate in juvenile-onset systemic lupus erythematosus publication-title: J. Clin. Immunol. – volume: 460849 year: 2020 ident: bb0135 article-title: Aging-related lipidomic changes in mouse serum, kidney, and heart by nanoflow ultrahigh-performance liquid chromatography-tandem mass spectrometry publication-title: J. Chromatogr. A – reference: T.J. Hoerger, J.S. Wittenborn, J.E. Segel, N.R. Burrows, K. Imai, P. Eggers, M.E. Pavkov, R. Jordan, S.M. Hailpern, A.C. Schoolwerth, D.E. Williams, A health policy model of CKD: 1. Model construction, assumptions, and validation of health consequences, American Journal of Kidney Diseases. 55 (2010) 452–462. doi: – volume: 107 start-page: 18439 year: 2010 end-page: 18444 ident: bb0175 article-title: ELOVL1 production of C24 acyl-CoAs is linked to C24 sphingolipid synthesis publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 283 start-page: 5677 year: 2008 end-page: 5684 ident: bb0145 article-title: Characterization of ceramide synthase 2 tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate publication-title: J. Biol. Chem. – volume: 34 start-page: 1001 year: 2000 ident: bb0185 article-title: Correlation between renal growth retardation and apoptosis of cortical tubules in experimentally induced acute ascending pyelonephritis in infant rat publication-title: Korean J Pathol. – start-page: 109 year: 2019 end-page: 138 ident: bb0035 article-title: Sphingolipids as biomarkers of disease publication-title: Bioactive Ceramides in Health and Disease: Intertwined Roles of Enigmatic Lipids – reference: R. Brunkhorst, W. Pfeilschifter, S. Patyna, S. Büttner, T. Eckes, S. Trautmann, D. Thomas, J. Pfeilschifter, A. Koch, Preanalytical biases in the measurement of human blood sphingolipids, Int J Mol Sci. 19 (2018). doi: – volume: 62 start-page: 347 year: 2010 end-page: 356 ident: bb0140 article-title: Mammalian ceramide synthases publication-title: IUBMB Life – volume: 32 start-page: 1313 year: 2017 end-page: 1322 ident: bb0060 article-title: Sphingosine-1-phosphate and its receptors in anti-neutrophil cytoplasmic antibody-associated vasculitis publication-title: Nephrol. Dial. Transplant. – volume: 38 start-page: 1933 year: 2018 end-page: 1939 ident: bb0050 article-title: Plasma ceramides publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 285 start-page: 10902 year: 2010 end-page: 10910 ident: bb0150 article-title: A critical role for ceramide synthase 2 in liver homeostasis publication-title: J. Biol. Chem. – volume: 285 start-page: 11818 year: 2010 end-page: 11826 ident: bb0160 article-title: The BCL-2 protein BAK is required for long-chain ceramide generation during apoptosis publication-title: J. Biol. Chem. – volume: 390 start-page: 263 year: 2005 end-page: 271 ident: bb0170 article-title: Mammalian Lass6 and its related family members regulate synthesis of specific ceramides publication-title: Biochem. J. – reference: M. Uhlén, L. Fagerberg, B.M. Hallström, C. Lindskog, P. Oksvold, A. Mardinoglu, Å. Sivertsson, C. Kampf, E. Sjöstedt, A. Asplund, I. Olsson, K. Edlund, E. Lundberg, S. Navani, C.A.-K. Szigyarto, J. Odeberg, D. Djureinovic, J.O. Takanen, S. Hober, T. Alm, P.-H. Edqvist, H. Berling, H. Tegel, J. Mulder, J. Rockberg, P. Nilsson, J.M. Schwenk, M. Hamsten, K. von Feilitzen, M. Forsberg, L. Persson, F. Johansson, M. Zwahlen, G. von Heijne, J. Nielsen, F. Pontén, Tissue-based map of the human proteome, Science. 347 (2015). doi: – volume: 63 start-page: 93 year: 2016 end-page: 119 ident: bb0180 article-title: The enigma of ceramide synthase regulation in mammalian cells publication-title: Prog. Lipid Res. – reference: G. Grammatikos, J. Dietz, N. Ferreiros, A. Koch, G. Dultz, D. Bon, I. Karakasiliotis, T. Lutz, G. Knecht, P. Gute, E. Herrmann, S. Zeuzem, P. Mavromara, C. Sarrazin, J. Pfeilschifter, Persistence of HCV in acutely-infected patients depletes C24-ceramide and upregulates sphingosine and sphinganine serum levels, Int J Mol Sci. 17 (2016). doi: – volume: 26 start-page: 1023 year: 2017 end-page: 1033 ident: bb0075 article-title: Dysregulations in circulating sphingolipids associate with disease activity indices in female patients with systemic lupus erythematosus: a cross-sectional study publication-title: Lupus. – volume: 19 start-page: 175 year: 2018 end-page: 191 ident: bb0020 article-title: Sphingolipids and their metabolism in physiology and disease publication-title: Nat. Rev. Mol. Cell Biol. – volume: 101 start-page: 2070 year: 2004 end-page: 2075 ident: bb0100 article-title: Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease publication-title: Proc. Natl. Acad. Sci. U. S. A. – year: 2017 ident: bb0115 article-title: Sphingosine kinase-2 deficiency ameliorates kidney fibrosis by up-regulating Smad7 in a mouse model of unilateral ureteral obstruction, The American Journal of Pathology – volume: 15 start-page: 6068 year: 2009 end-page: 6074 ident: bb0105 article-title: Elevated pro-inflammatory and lipotoxic mucosal lipids characterise irritable bowel syndrome publication-title: World J. Gastroenterol. – volume: 144 start-page: 106348 year: 2019 ident: bb0090 article-title: Blood ceramides as novel markers for renal impairment in systemic lupus erythematosus publication-title: Prostaglandins Other Lipid Mediat. – reference: T.V. Dupre, M.A. Doll, P.P. Shah, C.N. Sharp, D. Siow, J. Megyesi, J. Shayman, A. Bielwska, J. Bielawski, L.J. Beverly, others, Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury, Journal of Lipid Research. (2017) jlr–M076745. – reference: H. Geidis, Praktische Mikroskopie, in: Praktische Mikroskopie, 1935: p. 28f. – reference: . – volume: 29 start-page: 415 year: 2014 end-page: 422 ident: bb0085 article-title: CKiD study group, Ceramides and cardiac function in children with chronic kidney disease publication-title: Pediatr. Nephrol. – volume: 51 start-page: 50 year: 2012 end-page: 62 ident: bb0025 article-title: Chain length-specific properties of ceramides publication-title: Prog. Lipid Res. – volume: 58 start-page: 337 year: 2009 end-page: 343 ident: bb0045 article-title: Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance publication-title: Diabetes. – volume: 36 start-page: 2424 year: 2016 end-page: 2430 ident: bb0055 article-title: Circulating ceramides predict cardiovascular outcomes in the population-based FINRISK 2002 cohort publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 26 start-page: 1402 year: 2015 end-page: 1413 ident: bb0110 article-title: Renal glycosphingolipid metabolism is dysfunctional in lupus nephritis publication-title: J. Am. Soc. Nephrol. – volume: 28 start-page: 3590 year: 2017 end-page: 3604 ident: bb0120 article-title: Macrophage migration inhibitory factor limits renal inflammation and fibrosis by counteracting tubular cell cycle arrest publication-title: JASN. – volume: 48 start-page: 1264 year: 2015 end-page: 1267 ident: bb0070 article-title: The effect of nephropathy on plasma sphingosine 1-phosphate concentrations in patients with type 2 diabetes publication-title: Clin. Biochem. – volume: 182 start-page: 369 year: 2010 end-page: 375 ident: bb0095 article-title: Ceramide is increased in the lower airway epithelium of people with advanced cystic fibrosis lung disease publication-title: Am. J. Respir. Crit. Care Med. – volume: 291 start-page: 7477 year: 2016 end-page: 7487 ident: bb0165 article-title: Enzyme activities of the ceramide synthases CERS2–6 are regulated by phosphorylation in the C-terminal region publication-title: J. Biol. Chem. – volume: 12 start-page: 98 year: 2013 ident: bb0080 article-title: Role of ceramide in diabetes mellitus: evidence and mechanisms publication-title: Lipids Health Dis. – volume: 70 start-page: 1735 year: 2006 end-page: 1741 ident: bb0190 article-title: Osteopontin regulates renal apoptosis and interstitial fibrosis in neonatal chronic unilateral ureteral obstruction publication-title: Kidney Int. – volume: 209 start-page: 120593 year: 2020 ident: bb0130 article-title: Implementation of lipidomics in clinical routine: can fluoride/citrate blood sampling tubes improve preanalytical stability? publication-title: Talanta. – ident: 10.1016/j.bbalip.2020.158821_bb0040 doi: 10.3390/ijms17060922 – ident: 10.1016/j.bbalip.2020.158821_bb0010 doi: 10.1053/j.ajkd.2009.11.016 – volume: 32 start-page: 1313 year: 2017 ident: 10.1016/j.bbalip.2020.158821_bb0060 article-title: Sphingosine-1-phosphate and its receptors in anti-neutrophil cytoplasmic antibody-associated vasculitis publication-title: Nephrol. Dial. Transplant. doi: 10.1093/ndt/gfw427 – ident: 10.1016/j.bbalip.2020.158821_bb0155 doi: 10.1126/science.1260419 – ident: 10.1016/j.bbalip.2020.158821_bb0030 doi: 10.3390/ijms19051390 – volume: 15 start-page: 6068 year: 2009 ident: 10.1016/j.bbalip.2020.158821_bb0105 article-title: Elevated pro-inflammatory and lipotoxic mucosal lipids characterise irritable bowel syndrome publication-title: World J. Gastroenterol. doi: 10.3748/wjg.15.6068 – volume: 58 start-page: 337 year: 2009 ident: 10.1016/j.bbalip.2020.158821_bb0045 article-title: Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance publication-title: Diabetes. doi: 10.2337/db08-1228 – volume: 107 start-page: 18439 year: 2010 ident: 10.1016/j.bbalip.2020.158821_bb0175 article-title: ELOVL1 production of C24 acyl-CoAs is linked to C24 sphingolipid synthesis publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1005572107 – volume: 38 start-page: 1933 year: 2018 ident: 10.1016/j.bbalip.2020.158821_bb0050 article-title: Plasma ceramides publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/ATVBAHA.118.311199 – start-page: 109 year: 2019 ident: 10.1016/j.bbalip.2020.158821_bb0035 article-title: Sphingolipids as biomarkers of disease – volume: 209 start-page: 120593 year: 2020 ident: 10.1016/j.bbalip.2020.158821_bb0130 article-title: Implementation of lipidomics in clinical routine: can fluoride/citrate blood sampling tubes improve preanalytical stability? publication-title: Talanta. doi: 10.1016/j.talanta.2019.120593 – volume: 36 start-page: 2424 year: 2016 ident: 10.1016/j.bbalip.2020.158821_bb0055 article-title: Circulating ceramides predict cardiovascular outcomes in the population-based FINRISK 2002 cohort publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/ATVBAHA.116.307497 – volume: 48 start-page: 1264 year: 2015 ident: 10.1016/j.bbalip.2020.158821_bb0070 article-title: The effect of nephropathy on plasma sphingosine 1-phosphate concentrations in patients with type 2 diabetes publication-title: Clin. Biochem. doi: 10.1016/j.clinbiochem.2015.08.001 – volume: 291 start-page: 7477 year: 2016 ident: 10.1016/j.bbalip.2020.158821_bb0165 article-title: Enzyme activities of the ceramide synthases CERS2–6 are regulated by phosphorylation in the C-terminal region publication-title: J. Biol. Chem. doi: 10.1074/jbc.M115.695858 – volume: 26 start-page: 1023 year: 2017 ident: 10.1016/j.bbalip.2020.158821_bb0075 article-title: Dysregulations in circulating sphingolipids associate with disease activity indices in female patients with systemic lupus erythematosus: a cross-sectional study publication-title: Lupus. doi: 10.1177/0961203316686707 – year: 2017 ident: 10.1016/j.bbalip.2020.158821_bb0115 – volume: 73 start-page: A7 year: 2019 ident: 10.1016/j.bbalip.2020.158821_bb0005 article-title: 2018 annual data report: epidemiology of kidney disease in the United States publication-title: Am. J. Kidney Dis. doi: 10.1053/j.ajkd.2019.01.001 – ident: 10.1016/j.bbalip.2020.158821_bb0125 – volume: 390 start-page: 263 year: 2005 ident: 10.1016/j.bbalip.2020.158821_bb0170 article-title: Mammalian Lass6 and its related family members regulate synthesis of specific ceramides publication-title: Biochem. J. doi: 10.1042/BJ20050291 – volume: 101 start-page: 2070 year: 2004 ident: 10.1016/j.bbalip.2020.158821_bb0100 article-title: Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.0305799101 – volume: 26 start-page: 1402 year: 2015 ident: 10.1016/j.bbalip.2020.158821_bb0110 article-title: Renal glycosphingolipid metabolism is dysfunctional in lupus nephritis publication-title: J. Am. Soc. Nephrol. doi: 10.1681/ASN.2014050508 – volume: 12 start-page: 98 year: 2013 ident: 10.1016/j.bbalip.2020.158821_bb0080 article-title: Role of ceramide in diabetes mellitus: evidence and mechanisms publication-title: Lipids Health Dis. doi: 10.1186/1476-511X-12-98 – volume: 62 start-page: 347 year: 2010 ident: 10.1016/j.bbalip.2020.158821_bb0140 article-title: Mammalian ceramide synthases publication-title: IUBMB Life doi: 10.1002/iub.319 – volume: 63 start-page: 93 year: 2016 ident: 10.1016/j.bbalip.2020.158821_bb0180 article-title: The enigma of ceramide synthase regulation in mammalian cells publication-title: Prog. Lipid Res. doi: 10.1016/j.plipres.2016.03.006 – volume: 285 start-page: 10902 year: 2010 ident: 10.1016/j.bbalip.2020.158821_bb0150 article-title: A critical role for ceramide synthase 2 in liver homeostasis publication-title: J. Biol. Chem. doi: 10.1074/jbc.M109.077594 – volume: 460849 year: 2020 ident: 10.1016/j.bbalip.2020.158821_bb0135 article-title: Aging-related lipidomic changes in mouse serum, kidney, and heart by nanoflow ultrahigh-performance liquid chromatography-tandem mass spectrometry publication-title: J. Chromatogr. A – volume: 32 start-page: 1019 year: 2012 ident: 10.1016/j.bbalip.2020.158821_bb0065 article-title: Increased serum concentration of sphingosine-1-phosphate in juvenile-onset systemic lupus erythematosus publication-title: J. Clin. Immunol. doi: 10.1007/s10875-012-9710-3 – volume: 144 start-page: 106348 year: 2019 ident: 10.1016/j.bbalip.2020.158821_bb0090 article-title: Blood ceramides as novel markers for renal impairment in systemic lupus erythematosus publication-title: Prostaglandins Other Lipid Mediat. doi: 10.1016/j.prostaglandins.2019.106348 – volume: 283 start-page: 5677 year: 2008 ident: 10.1016/j.bbalip.2020.158821_bb0145 article-title: Characterization of ceramide synthase 2 tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate publication-title: J. Biol. Chem. doi: 10.1074/jbc.M707386200 – volume: 19 start-page: 175 year: 2018 ident: 10.1016/j.bbalip.2020.158821_bb0020 article-title: Sphingolipids and their metabolism in physiology and disease publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm.2017.107 – volume: 29 start-page: 415 year: 2014 ident: 10.1016/j.bbalip.2020.158821_bb0085 article-title: CKiD study group, Ceramides and cardiac function in children with chronic kidney disease publication-title: Pediatr. Nephrol. doi: 10.1007/s00467-013-2642-1 – volume: 28 start-page: 3590 year: 2017 ident: 10.1016/j.bbalip.2020.158821_bb0120 article-title: Macrophage migration inhibitory factor limits renal inflammation and fibrosis by counteracting tubular cell cycle arrest publication-title: JASN. doi: 10.1681/ASN.2017020190 – volume: 182 start-page: 369 year: 2010 ident: 10.1016/j.bbalip.2020.158821_bb0095 article-title: Ceramide is increased in the lower airway epithelium of people with advanced cystic fibrosis lung disease publication-title: Am. J. Respir. Crit. Care Med. doi: 10.1164/rccm.200905-0799OC – volume: 70 start-page: 1735 year: 2006 ident: 10.1016/j.bbalip.2020.158821_bb0190 article-title: Osteopontin regulates renal apoptosis and interstitial fibrosis in neonatal chronic unilateral ureteral obstruction publication-title: Kidney Int. doi: 10.1038/sj.ki.5000357 – volume: 51 start-page: 50 year: 2012 ident: 10.1016/j.bbalip.2020.158821_bb0025 article-title: Chain length-specific properties of ceramides publication-title: Prog. Lipid Res. doi: 10.1016/j.plipres.2011.11.001 – ident: 10.1016/j.bbalip.2020.158821_bb0195 doi: 10.1194/jlr.M076745 – volume: 285 start-page: 11818 year: 2010 ident: 10.1016/j.bbalip.2020.158821_bb0160 article-title: The BCL-2 protein BAK is required for long-chain ceramide generation during apoptosis publication-title: J. Biol. Chem. doi: 10.1074/jbc.M109.078121 – ident: 10.1016/j.bbalip.2020.158821_bb0015 – volume: 34 start-page: 1001 year: 2000 ident: 10.1016/j.bbalip.2020.158821_bb0185 article-title: Correlation between renal growth retardation and apoptosis of cortical tubules in experimentally induced acute ascending pyelonephritis in infant rat publication-title: Korean J Pathol. |
| SSID | ssj0015335 |
| Score | 2.392671 |
| Snippet | Several studies revealed alterations of single sphingolipid species, such as chain length-specific ceramides, in plasma and serum of patients with kidney... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 158821 |
| SubjectTerms | Actins - genetics Actins - metabolism Adenine - administration & dosage Aged Animals biomarkers Biomarkers - metabolism blood serum Ceramide ceramides Ceramides - classification Ceramides - metabolism Collagen Type I - genetics Collagen Type I - metabolism Collagen Type III - genetics Collagen Type III - metabolism cortex diet Disease Models, Animal Female Fibrosis Gene Expression Regulation Humans Hydronephrosis - chemically induced Hydronephrosis - genetics Hydronephrosis - metabolism Hydronephrosis - pathology Kidney Kidney - metabolism Kidney - pathology kidneys Lipid mediator Lipid Metabolism - genetics Male males Mice Mice, Inbred C57BL Middle Aged neoplasms Nephropathy pyelonephritis Pyelonephritis - chemically induced Pyelonephritis - genetics Pyelonephritis - metabolism Pyelonephritis - pathology Sphingolipids Sphingolipids - classification Sphingolipids - metabolism Ureteral Obstruction - genetics Ureteral Obstruction - metabolism Ureteral Obstruction - pathology |
| Title | Consistent alteration of chain length-specific ceramides in human and mouse fibrotic kidneys |
| URI | https://dx.doi.org/10.1016/j.bbalip.2020.158821 https://www.ncbi.nlm.nih.gov/pubmed/33010454 https://www.proquest.com/docview/2448408285 https://www.proquest.com/docview/2524318605 |
| Volume | 1866 |
| WOSCitedRecordID | wos000592664200010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1879-2618 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0015335 issn: 1388-1981 databaseCode: AIEXJ dateStart: 19981208 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb5RAFJ5sW42-GG2t1kszJsaXDc1yGZh5XGuN-tCYtCb7YEJmYMiCu7DZsk37z_x5nrmBW21rH3whBIYJ8H3MuXAuCL3NpC9AzDBPZGHsRXkUeVSAlSJpkhdxDiKHZLrZRHJ8TCcT9nUw-OlyYc5nSV3Tiwu2-K9QwzEAW6XO3gHublI4APsAOmwBdtj-E_C6BSdgp2LHZ7pmstUJsykv66HqnNJOPZVhqaKEhhmMmJe5jsuyHfuUL115BOSwAGO6USVdf5R5DZiv_QIum2xaqmoDQ9kORdkYJwlX5Tn4ASwWtu-uyZxTLkJX8KlRmc-LMu_VeVhKzhxz-sjgJV-1c9vE-QRmWXYi5EO1yiuufzydNHXVOxXkpW0k1g-3Lo3A_82lYVbhEDD1menl0i_Tpj3LGiHNqusTsBP8vwoE45uoDoQAs0bVJw2UM80NX6-_fUUudtGKLhCuSs0sqZolNbNsoK0gIQzW063x56PJl-4PFqjRRBv79lFc2qaOLfzzbq5Ti64ze7T6c_oYPbJ2Cx4bvj1BA1lvo51xzdtmfonfYR1JrOHdRvffu70Hh66f4A763hMT98TETYE1MfEVYuKOmBhOamJiABVrYmJHTGyJ-RR9-3h0evjJs709vCxkpPXynESCZlFB2SgRo1iCBuUHRRxwUIFDQeSoAOnDGKfKYAlIyAMOCpcUghKZkTjcRZt1U8vnCEvVVrIANTeMCjD3AwY2MIgaSpQrg-dsD4Xu1aaZLXyv-q_M0puA3UNed9XCFH65ZXziUEut8mqU0hSoeMuVbxzIKUCiPkheS3iZKajeNNI1Jm8YQwKwAWg8gjHPDEO6-w1D5W0h0Ys7PstL9LD_LF-hzXa5kq_Rvey8Lc-W-2gjmdB9y_dfKBHesw |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Consistent+alteration+of+chain+length-specific+ceramides+in+human+and+mouse+fibrotic+kidneys&rft.jtitle=Biochimica+et+biophysica+acta.+Molecular+and+cell+biology+of+lipids&rft.au=Eckes%2C+Timon&rft.au=Trautmann%2C+Sandra&rft.au=Djudjaj%2C+Sonja&rft.au=Beyer%2C+Sandra&rft.date=2021-01-01&rft.issn=1388-1981&rft.volume=1866&rft.issue=1&rft.spage=158821&rft_id=info:doi/10.1016%2Fj.bbalip.2020.158821&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_bbalip_2020_158821 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1388-1981&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1388-1981&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1388-1981&client=summon |